Does anyone know how much Acadia spent on the Trofinetide Ph3 trial?
I'd like to try to quantify the cost of the NNZ-2591 Ph3 trials, and consider how it may be funded.
A mixture of Trof revenue and debt would be my preference (rather than through another capital raise). This would mean that NEU would need to keep all incoming revenue, rather than paying any dividends (which I think would be the more prudent course to take).
Ann: Rett Syndrome NDA accepted for Priority Review by FDA, page-25
-
- There are more pages in this discussion • 139 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$21.27 |
Change
0.650(3.15%) |
Mkt cap ! $2.718B | |||
| Open | High | Low | Value | Volume |
| $20.84 | $21.56 | $20.76 | $7.760M | 364.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1378 | $21.24 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $21.29 | 218 | 1 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| NEU (ASX) Chart |